
## Instructions for reporting data to the 2019 and 2020 survey of cellular therapy and regenerative medicine in Europe and neighboring Eurasian countries

The definition of novel cell therapies or engineered tissues is any clinical treatment based on living cells excluding:


- DLIs Donor Lymphocyte Infusions
- Non-manipulated hematopoietic cells for hematological reconstitution (these treatments should be reported using the companion EBMT activity survey)
- CAR-T cell therapy


Each year of treatment requires a separate survey sheet, which are to be filled out as described below. For this example we use 2020.

Opening the survey you will see the layout below. Excel may ask you to "Enable content". Please do so.




1) Enter each team member and indicate their affiliation by clicking the blue buttons on the left. These details will be reported in the appendix of the published report.






2a) If you did not perform such therapies in 2020, but have in the past or plan to in the future, please click the red button on the left hand side of the Survey. Please include a contact person with respective contact details and affiliation as Team member 1. Please send the survey to MaxHPG@outlook.com






2b) If you treated Patients in 2020 please click the green button on the left.



6) If further therapies were performed please repeat steps 2b-5).

If one therapy has varying parameters please enter the data separately for each variation.

Example: 30 patients treated for heart failure with muscle cells. 20 Patients with autologous cells, 10 with allogenic. Perform steps 2b-5 for both conditions, which will appear in the table as seen below.



7) Save the file and send the completed activity survey to Max Gay MaxHPG@outlook.com

If you need help with submitting your data please contact Max Gay directly.